| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound does not have a biological target; it is a chemical catalyst. Its "target" is the substrate in a chemical reaction. It is a versatile catalyst for cross-coupling of aryl and vinyl chlorides. It is also used in the preparation of G6P-T1 translocase inhibitors for the treatment of diabetes.
|
|---|---|
| ln Vitro |
This compound is not a biological agent and has no in vitro biological activity. Its chemical activity is as a catalyst. It is used in coupling reactions and greener Heck reactions. It also acts as a palladium catalyst for reductive carbonylation. Its efficiency is measured by reaction yield and selectivity.
|
| ln Vivo |
This compound is not used in in vivo studies as a therapeutic agent. It is a research chemical used as a catalyst in organic synthesis to create drug candidates. Its presence is typically removed from the final product through purification.
|
| Enzyme Assay |
Non-cellular assays are not applicable. Its "activity" is assessed in chemical reactions. A typical protocol involves combining the catalyst with a substrate (e.g., an aryl chloride), a coupling partner (e.g., a boronic acid or stannane), and a base in a solvent. The reaction is heated, and the progress is monitored. The catalyst facilitates the formation of a new carbon-carbon bond.
|
| Cell Assay |
This compound is not used in cell-based assays. It is a catalyst used in synthetic chemistry. It is handled under an inert atmosphere. It is a solid that is stable under normal conditions. It is not suitable for direct application in biological systems.
|
| Animal Protocol |
In vivo animal experiments do not involve this compound as a test article. It is a chemical reagent for synthesis. If used to synthesize a drug candidate, that candidate would be tested in animals. The palladium catalyst itself is not administered.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable as this is not a drug. It is a coordination complex of palladium(0) with two bulky phosphine ligands. Its properties are relevant for its use as a catalyst, not as a systemically available compound. It is sensitive to air and moisture.
|
| Toxicity/Toxicokinetics |
The toxicity of palladium compounds is a concern. Specific data for this complex is limited. It is a research chemical and should be handled with care, as palladium salts can be toxic and sensitizing. Standard laboratory safety practices, including the use of PPE and working in a fume hood, should be followed. It is not intended for human or veterinary use.
|
| Additional Infomation |
Bis(tri-tert-butylphosphine)palladium(0) is a highly active and versatile palladium catalyst for cross-coupling reactions. Its bulky ligand (P(t-Bu)₃) is key to its high activity and selectivity, particularly in reactions with challenging substrates like aryl chlorides. It is not a pharmaceutical and has no clinical trials or approved therapeutic status.
|
| Molecular Formula |
C24H54P2PD
|
|---|---|
| Molecular Weight |
511.05
|
| Exact Mass |
510.273
|
| CAS # |
53199-31-8
|
| PubChem CID |
2734558
|
| Appearance |
Off-white to yellow solid powder
|
| Boiling Point |
229.4ºC at 760mmHg
|
| Melting Point |
>300 °C
|
| Flash Point |
94.6ºC
|
| LogP |
9.727
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C.[Pd]
|
| InChi Key |
MXQOYLRVSVOCQT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C12H27P.Pd/c2*1-10(2,3)13(11(4,5)6)12(7,8)9;/h2*1-9H3;
|
| Chemical Name |
palladium;tritert-butylphosphane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9568 mL | 9.7838 mL | 19.5676 mL | |
| 5 mM | 0.3914 mL | 1.9568 mL | 3.9135 mL | |
| 10 mM | 0.1957 mL | 0.9784 mL | 1.9568 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
